Inhibiting the turnover of mutant proteins has been investigated as a possible therapeutic treatment for dominant negative mutations in caveolin-3 associated with limb-girdle muscular dystrophy (Galbiati et al., 2000). The gene discussed is CAV3; the disease is limb-girdle muscular dystrophy.